Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399208 | 0.81 | CHRM2 (0.47) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6593469 | 0.72 | KEAP1 (0.63) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2596487 | 0.71 | KEAP1 (0.50) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL5701311 | 0.71 | KEAP1 (0.61) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL6399095 | 0.70 | CHRM2 (0.47) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL523867 | 0.70 | CHRM3 (0.50) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL17871674 | 0.70 | ALDH1A1 (0.52) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4186775 | 0.69 | CHRM3 (0.55) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL4187396 | 0.69 | KEAP1 (0.39) | KEAP1NFE2L2KCNH2CYP2D6SLC6A3 | |
| SCHEMBL2062949 | 0.69 | KEAP1 (1.00) | KEAP1NFE2L2CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | KEAP1 1899/4885NFE2L2 3843/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.